Multimodal treatment of non-small-cell lung cancer
Mené sur 232 patients atteints d'un cancer du poumon non à petites cellules de stade IIIA/N2 traité entre 2001 et 2012, cet essai international de phase III (Suisse, Allemagne, Serbie) évalue, du point de vue de la survie sans événement et de la toxicité, l'intérêt d'une radiothérapie avant un traitement combinant une chimiothérapie d'induction et une intervention chirurgicale
In The Lancet, Miklos Pless and colleagues report a prospective randomised trial of induction chemotherapy followed by accelerated radiotherapy and surgery, compared with induction chemotherapy followed by surgery, to treat patients with stage IIIA/N2 non-small-cell lung cancer. 232 patients were enrolled in 23 study centres and were randomly assigned to the study groups in a 1:1 ratio. Median event-free survival, the trial's primary endpoint, was similar in the two groups (12·8 months, 95% CI 9·7–22·9 in the chemoradiotherapy group and 11·6 months, 8·4–15·2 in the chemotherapy group), as was overall survival (37·1 months [22·6–50·0] and 26·2 months, 19·9–52·1, respectively).
The Lancet , commentaire, 2014